New radioactive drug targets tough prostate cancer in early trial
Disease control
Recruiting now
This early study tests a new drug called 3D1015 in 8 men with a hard-to-treat type of advanced prostate cancer (mCRPC). The drug delivers a small amount of radiation directly to cancer cells. The main goals are to check safety and find the best dose. This is a first step to see i…
Phase: PHASE1 • Sponsor: Chunjing Yu • Aim: Disease control
Last updated May 04, 2026 16:32 UTC